EP2405754A4 - PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF BUPRENORPHINE - Google Patents

PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF BUPRENORPHINE

Info

Publication number
EP2405754A4
EP2405754A4 EP09841608.4A EP09841608A EP2405754A4 EP 2405754 A4 EP2405754 A4 EP 2405754A4 EP 09841608 A EP09841608 A EP 09841608A EP 2405754 A4 EP2405754 A4 EP 2405754A4
Authority
EP
European Patent Office
Prior art keywords
buprenorphine
pharmaceutical compositions
modified release
release
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09841608.4A
Other languages
German (de)
French (fr)
Other versions
EP2405754A1 (en
Inventor
Najib Babul
Ashish Kumar Rehni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Relmada Therapeutics Inc
Original Assignee
Relmada Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/001502 external-priority patent/WO2009114118A2/en
Application filed by Relmada Therapeutics Inc filed Critical Relmada Therapeutics Inc
Publication of EP2405754A1 publication Critical patent/EP2405754A1/en
Publication of EP2405754A4 publication Critical patent/EP2405754A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP09841608.4A 2009-03-09 2009-09-28 PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF BUPRENORPHINE Withdrawn EP2405754A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2009/001502 WO2009114118A2 (en) 2008-03-08 2009-03-09 Oral pharmaceutical compositions of buprenorphine and method of use
PCT/US2009/005394 WO2010104494A1 (en) 2009-03-09 2009-09-28 Modified release pharmaceutical compositions of buprenorphine

Publications (2)

Publication Number Publication Date
EP2405754A1 EP2405754A1 (en) 2012-01-18
EP2405754A4 true EP2405754A4 (en) 2015-10-14

Family

ID=42728703

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09841608.4A Withdrawn EP2405754A4 (en) 2009-03-09 2009-09-28 PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF BUPRENORPHINE

Country Status (2)

Country Link
EP (1) EP2405754A4 (en)
WO (1) WO2010104494A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10493027B2 (en) 2014-08-07 2019-12-03 Mucodel Pharma Llc Chemically stable compositions of a pharmaceutical active agent in a multi- chambered delivery system for mucosal delivery
US9682039B2 (en) * 2014-08-07 2017-06-20 Mucodel Pharma Llc Chemically stable and oromucosally absorbable gel compositions of a pharmaceutical active agent in a multi-chambered delivery system
WO2023187225A1 (en) * 2022-04-01 2023-10-05 Amplicon Ab Alkaline intraoral products
CN120000167B (en) * 2025-01-24 2025-10-28 中国人民解放军陆军军医大学第二附属医院 Intelligent pain detection and management system

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050226929A1 (en) * 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
WO2006069030A1 (en) * 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
WO2006079853A1 (en) * 2005-01-28 2006-08-03 Pharmakodex Ltd Analgesic compositions
US20070184112A1 (en) * 2002-03-29 2007-08-09 Alza Corporation Volume Efficient Controlled Release Dosage Form
EP1849460A2 (en) * 2005-10-31 2007-10-31 ALZA Corporation Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
WO2008086804A2 (en) * 2007-01-16 2008-07-24 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008134071A1 (en) * 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Multimodal abuse resistant extended release formulations
WO2008148798A2 (en) * 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2009114118A2 (en) * 2008-03-08 2009-09-17 Theraquest Biosciences, Inc. Oral pharmaceutical compositions of buprenorphine and method of use
WO2011018583A2 (en) * 2009-08-12 2011-02-17 Debregeas Et Associes Pharma Novel pharmaceutical formulations against drug misuse

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184112A1 (en) * 2002-03-29 2007-08-09 Alza Corporation Volume Efficient Controlled Release Dosage Form
US20050226929A1 (en) * 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
WO2006069030A1 (en) * 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
WO2006079853A1 (en) * 2005-01-28 2006-08-03 Pharmakodex Ltd Analgesic compositions
EP1849460A2 (en) * 2005-10-31 2007-10-31 ALZA Corporation Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
WO2008086804A2 (en) * 2007-01-16 2008-07-24 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008134071A1 (en) * 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Multimodal abuse resistant extended release formulations
WO2008148798A2 (en) * 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2009114118A2 (en) * 2008-03-08 2009-09-17 Theraquest Biosciences, Inc. Oral pharmaceutical compositions of buprenorphine and method of use
WO2011018583A2 (en) * 2009-08-12 2011-02-17 Debregeas Et Associes Pharma Novel pharmaceutical formulations against drug misuse

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010104494A1 *

Also Published As

Publication number Publication date
WO2010104494A1 (en) 2010-09-16
EP2405754A1 (en) 2012-01-18

Similar Documents

Publication Publication Date Title
EP2616076A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0909780A2 (en) Compositions and methods for drug release
LT3222272T (en) PHARMACEUTICAL COMPOSITION OF CARBETOCINE
SMT201700008B (en) PHARMACEUTICAL COMPOSITION
EP2637696A4 (en) EXTENDED RELEASE COMPOSITION
BRPI0919466A2 (en) modified release pharmaceutical composition
DK3097925T3 (en) PHARMACEUTICAL COMPOSITION
BRPI1011587A2 (en) therapeutic compounds and compositions
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI1004940A2 (en) pharmaceutical composition
PT2435030E (en) CONTROLLED RELEASE FLOATING PHARMACEUTICAL COMPOSITIONS
HUE065114T2 (en) Monochlorotrifluoropropene compounds and compositions and methods using them
EP2515946A4 (en) NANOCONJUGATES AND COMPOSITIONS OF NANOCONJUGATES
BRPI1006186A2 (en) immediate release pharmaceutical compositions comprising oxycodone and naloxone
BRPI1012539A2 (en) pharmaceutical compositions
BR112012004525A2 (en) gastric-profitable pharmaceutical compositions for immediate or prolonged release of acetaminophen
BRPI1015939A2 (en) pharmaceutical composition
EP2616053A4 (en) PHARMACEUTICAL COMPOSITIONS OF CURCUMIN
BR112012010201A2 (en) modified release formulation of lacosamide
EE201300005A (en) Pharmaceutical composition
BRPI0812250A2 (en) SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROParticles
IT1394400B1 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0912428A2 (en) solid delayed release pharmaceutical formulation
EP2341773A4 (en) PHARMACEUTICAL COMPOSITIONS OF ATORVASTATIN

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111010

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RELMADA THERAPEUTICS, INC.

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150914

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20150908BHEP

Ipc: A61K 9/20 20060101ALI20150908BHEP

Ipc: A61K 31/44 20060101ALI20150908BHEP

Ipc: A01N 43/42 20060101AFI20150908BHEP

Ipc: A61K 9/24 20060101ALI20150908BHEP

Ipc: A61K 9/28 20060101ALI20150908BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20161118

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220104